PATENT CLAIM ANALYSIS

Application Number: 16288374
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "006500"]

Abstract:
The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.

Claim (Index 20):
The method of  claim 18 , wherein the patient is a naive type 2 diabetes patient with insufficient glycemic control by diet and exercise alone, wherein linagliptin is used in monotherapy, or in initial combination therapy with an antidiabetic agent selected from the group consisting of metformin, thiazolidinediones, sulphonylureas, glinides, \u03b1-glucosidase inhibitors, and insulin or insulin analogues.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 99.0
- Lexical Diversity: 1.04167
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15616974', '14928048', '15354053', '14633489', '13295174']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7887103339837609
- 35 USC 102 Novelty (BERT): 0.588360925504468
- Combined Prediction Score: 0.7686753931358316
- Mean Citation Score: 402.637482
- Max Citation Score: 575.4381
- Similarity Product: 405.4508592597484

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test